Emerging data suggest Retatrutide , a dual activator targeting both GLP-1 and GIP , may offer a notable advancement for obesity treatment. Initial patient tests have indicated considerable losses in visceral fat , potentially surpassing current weight-loss treatments. However , additional study is required to completely determine its long-term effe